Theertha is at the forefront of biosimilar drug development, capitalizing on the surge of monoclonal antibody approvals in recent years. Drawing from extensive experience, our team is commencing the development of carefully selected biosimilar candidates, with a keen focus on monoclonal antibodies used in targeted therapies for conditions like cancer, autoimmune disorders, and infectious diseases. By thoroughly analyzing factors such as patent expiration, market size, and clinical profiles, we've curated our next wave of candidates. Our approach emphasizes a precise selection process and the potential for collaborations or client-based partnerships. Join Theertha in advancing accessible solutions within the competitive landscape of monoclonal antibody therapies, contributing to the vital mission of affordable and quality healthcare.